Evidence map›Paper›PMID 41510380›Full record

ArticleTranslational lung cancer research2025

Exon-level

Seong-Eun Kim, Yongjae Kim, Do Kyung Yoon, Hwan Park, Kang-Seo Park, Deokhoon Kim, Hee Sang Hwang, Bokyung Ahn, Ji Eun Park, Sang-We Kim and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Seong-Eun Kim *Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.ORCID https://orcid.org/0009-0000-2584-3870
Yongjae Kim *Department of Biochemistry and Molecular Biology, Asan Medical Center, Brain Korea 21 Project, University of Ulsan College of Medicine, Seoul, Korea.
Do Kyung YoonDepartment of Biochemistry and Molecular Biology, Asan Medical Center, Brain Korea 21 Project, University of Ulsan College of Medicine, Seoul, Korea.
Hwan ParkDepartment of Biochemistry and Molecular Biology, Asan Medical Center, Brain Korea 21 Project, University of Ulsan College of Medicine, Seoul, Korea.
Kang-Seo ParkDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Deokhoon KimDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Hee Sang HwangDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Bokyung AhnDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Ji Eun ParkDepartment of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Sang-We KimDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Se Jin JangDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Shinkyo YoonDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Ho-Su LeeDepartment of Biochemistry and Molecular Biology, Asan Medical Center, Brain Korea 21 Project, University of Ulsan College of Medicine, Seoul, Korea.
Dae Ho LeeDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Osimertinib is the standard first-line treatment for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor ( Methods: Clinical data were extracted from electronic medical records. We retrospectively analyzed next-generation sequencing (NGS) data for Results: Among the patients who underwent first-line osimertinib treatment, baseline NGS data were analyzed from treatment-naïve tissue for 48 patients. Alterations in Conclusions: Mutations in

Indexed as

Epidermal growth factornon-small cell lung cancer (NSCLC)osimertinib

Identifiers

PMID41510380
PMCPMC12775692

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.